Delving into the Latest Updates on Amicrobe, Inc. with Synapse

概览

疾病领域	数量

感染	3

排名前五的药物类型	数量

融合蛋白	4

关联

5

项与 Amicrobe, Inc. 相关的药物

Amicidin-α Surgical

靶点-

作用机制-

在研机构

Amicrobe, Inc.

原研机构

Amicrobe, Inc.

在研适应症

术后感染

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

Amicidin-β Solution

靶点-

作用机制-

在研机构

Amicrobe, Inc.

原研机构

Amicrobe, Inc.

在研适应症

感染

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

Amicidin-β/EF

靶点-

作用机制-

在研机构

Amicrobe, Inc.

原研机构

Amicrobe, Inc.

在研适应症

感染

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

100 项与 Amicrobe, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Amicrobe, Inc. 相关的专利（医药）

登录后查看更多信息

8

项与 Amicrobe, Inc. 相关的文献（医药）

Polymer Preprints (American Chemical Society, Division of Polymer Chemistry)

Antimicrobial block co-polypeptide hydrogels

作者: Hanson, Jarrod A. ; Chow, Janet ; Deming, Timothy J. ; Bevilacqua, Michael P. ; Ogilby, Kevin R. ; Benitez, Diego

Antimicrobial block co-polypeptide hydrogels were prepared in this study and its potential use was evaluated.

Antimicrobial block copolypeptide hydrogels

作者: Hanson, Jarrod A. ; Chow, Janet ; Deming, Timothy J. ; Bevilacqua, Michael P. ; Ogilby, Kevin R. ; Benitez, Diego

Cationic antimicrobials have been used to fight infection for decades.Their mechanism of action limits development of microbial resistance.Amicrobe has developed long-chain, cationic block copolypeptide hydrogels with potent antimicrobial activity.Initial data suggest that these hydrogels are broadly antimicrobial, effective in surgical site infection (SSI) models, and biocompatible with tissues.An advantage of our synthetic approach is the ability to engineer chem. and phys. characteristics (e.g.hierarchical structures) that may improve efficacy and safety.Notably, these phys. hydrogels are not covalently cross-linked and, therefore, can flow upon (mild) deformation to fill wound cavities and rapidly re-gel.A lead candidate, A.GEL-1, has been shown to be antimicrobial, stable to various media, easy to apply, and biodegradable.We anticipate that A.GEL-1 will significantly reduce the occurrence of SSIs, as well as help prevent and treat infections of traumatic and chronic wounds.

Amicidin-α and amicidin-β: Amino acid block copolymers in development for prevention and treatment of infection in surgery and trauma

作者: Huang, Daniel J. ; Bevilacqua, Michael P. ; Deming, Timothy John

Amicidin-α and Amicidin-β are synthetic proteins with a lysine-leucine block architecture that combine three qualities into each mol.: (1) broad microbicidal activity (non-antibiotic); (2) optimized phys. properties; and (3) safety.Both are purpose-built for direct application to the exposed tissues of surgery and trauma.Amicidin-α (rel.MW ∼35kDa by SEC) at 2wt% in water forms a shear-thinning hydrogel that is easily spread on tissues to form a protective barrier (like collagens and keratins in skin) and brings microbicidal activity to help eliminate contaminating organisms.Amicidin-β (rel.MW ∼26kDa by SEC) forms micelles in aqueous media and acts as a biosurfactant for enhanced wound debridement and anti-biofilm properties.Both are manufactured by a robust, four-step process involving ring-opening polymerization of first block, second block, deprotection, and purificationIn-process controls and release analytics have been established and GMP manufacturing is underway.Both Amicidins have demonstrated rapid microbicidal activity against gram-pos. and gram-neg. bacteria, as well as yeast, including multidrug-resistant strains.Both have shown a high level of effectiveness and safety in clin. relevant animal models, including a deep tissue rodent orthopedic model of microbial contamination / infection.Amicidin-α Surgical Gel and Amicidin-β Solution are investigational products headed toward clin. trials.The clin. development plan (CDP) of the former focuses on intraoperative use to protect against microbial contamination and decrease the risk of surgical site infection in Class I (clean) and Class II (clean-contaminated) surgical procedures.The CDP of the latter focuses on intraoperative and post-operative use to decrease microbial load and treat extant infections, such as periprosthetic joint infection.If successful, these products should help prevent and treat life-threatening infections in the era of antibiotic resistance.

100 项与 Amicrobe, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Amicrobe, Inc. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2025年05月12日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

4

1

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Amicidin-β/EF	感染更多	临床前
Amicidin-α Surgical	术后感染更多	临床前
Amicidin-α PFC	感染更多	临床前
Amicidin-β Solution	感染更多	临床前
AB-100L	感染更多	无进展